However, hypoglycemia risk increases when these agents are combined with insulin or insulin secretagogues, necessitating dose adjustments of concomitant medications in many cases
Given the findings from the LEAD clinical trials, how would you evaluate the trade-offs between liraglutides benefits (e.g., glycemic control, weight loss) and its potential side effects, such as nausea or pancreatitis
Every injection
The FDAs drug information label now includes severe pancreatitis and severe kidney injuries
These typically present as mild erythema, bruising, or occasional nodules at injection sites, usually resolving spontaneously within days
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications originally developed for type 2 diabetes management that have demonstrated significant weight loss effects